The combination therapy of 5-azacytidine, Valproic Acid, and All-trans Retinoic Acid targets high-risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML), a significant market with unmet needs. The successful demonstration of safety and efficacy could position this combination as a competitive treatment option in a market dominated by existing therapies such as hypomethylating agents and chemotherapy. Given the increasing focus on combination therapies in oncology, this trial's outcomes could attract interest from pharmaceutical companies looking to enhance their portfolios in hematologic malignancies. The collaboration with Celgene Corporation indicates potential commercial interest and support for further development.